[Observation on the efficacy and safety of Infergen combined with capsule ribavirin in treatment of hepatitis C patients].
Luo
Guang-han
GH
Department of Infectious Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Liao
Bo-ming
BM
Huang
Shao-biao
SB
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects; D016898:Interferon-alpha; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D012449:Safety; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D007370:Interferon Type I; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin; C050739:interferon alfacon-1